Ganoderic Acid A |
カタログ番号GN10109
One-Click Copy Product Info
|
Ganoderic Acid Aは、霊芝（Ganoderma lucidumand）に由来するトリテルペノイド化合物であり、複数の生物活性を示す。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 81907-62-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ganoderic Acid Aは、霊芝（Ganoderma lucidumand）に由来するトリテルペノイド化合物であり、複数の生物活性を示す[1-2]。Ganoderic Acid Aは、癌、酸化、老化などに対して阻害作用を持っている[3-4]。
体外で、BV2小膠細胞をGanoderic Acid A (50μg/ml)とLPS (0.5μg/ml)で24時間共同処理した結果、BV2小膠細胞のLPS誘発の増殖と活性化を著しく抑制し、炎症促進M1表現型から抗炎症M2表現型への小膠細胞の分極を促進した[5]。Ganoderic Acid A (5–80μM)でMC3T3-E1細胞(1mM H₂O₂で誘発)と初代骨芽細胞(250μM H₂O₂で誘発)を24時間処理した結果、骨芽細胞分化と石灰化結節形成を著しく促進し、骨形成関連マーカーRUNX2、OPNとβ-cateninのタンパク質発見を上方制御した[6]。
体内で、Ovalbumin (0.1g)チャレンジの1時間前に、Ganoderic Acid A (20–40mg/kg)をOVA感作BALB/cマウスに腹腔内注射した結果、気道過敏性を著しく軽減し、気管支肺胞洗浄液における炎症細胞の総数を減らした[7]。Ganoderic Acid A (20mg/kg/日)を6日間、毎日腹腔内注射または局部塗布した結果、Imiquimod (62.5mg/マウス)誘発の乾癬性皮膚炎BALB/cマウスで、皮膚の紅斑、肥厚、鱗屑化を著しく改善し、乾癬面積重症度指数（PASI）スコアを下げた[8]。
References:
[1] Sui Q, Zhu C, Shi S, et al. Ganoderic acid A: an in-depth review of pharmacological effects and molecular docking analysis. J Ethnopharmacol. 2025 Jun 12;349:119868.
[2] Ma F, Wang J, Jiang W, et al. Ganoderic Acid A: A Potential Natural Neuroprotective Agent for Neurological Disorders: A Review. Int J Med Mushrooms. 2024;26(2):11-23.
[3] Zhang X, Huang S, Xu H, et al. Research progress on plant-derived natural compounds regulating the MAPK signaling pathway for the prevention and therapy of Alzheimer's disease. Front Pharmacol. 2025 Sep 19;16:1666082.
[4] Song Z, Wang C, Ding F, et al. Ganoderic Acid A Enhances Tumor Suppression Function of Oxaliplatin via Inducing the Cytotoxicity of T Cells. Anticancer Agents Med Chem. 2023;23(7):832-838.
[5] Jia Y, Zhang D, Yin H, et al. Ganoderic Acid A Attenuates LPS-Induced Neuroinflammation in BV2 Microglia by Activating Farnesoid X Receptor. Neurochem Res. 2021 Jul;46(7):1725-1736.
[6] Zhao J, Fan Y, Li H, et al. Ganoderic Acid A Prevented Osteoporosis by Modulating the PIK3CA/p-Akt/TWIST1 Signaling Pathway. Food Sci Nutr. 2025 Apr 14;13(4):e70177.
[7] Lu X, Xu C, Yang R, et al. Ganoderic Acid A Alleviates OVA-Induced Asthma in Mice. Inflammation. 2021 Oct;44(5):1908-1915.
[8] Xiao C, Chen J, Zhou X, et al. Ganoderic acid A alleviate psoriasis by inhibiting GSDMD-mediated pyroptosis. Tissue Cell. 2025 Dec;97:103078.
| 細胞実験[1]: | |
細胞株 | BV2小膠細胞（マウス小膠細胞株） |
準備方法 | 37°C、5% CO₂で、10%のウシ胎児血清（FBS）と1%のペニシリン-ストレプトマイシンを添加したDMEM高グルコース培地でBV2細胞を培養した。細胞を、50μg/mLのGanoderic Acid AとLPS (0.5μg/mL)で24時間共同処理した。 |
反応条件 | 50μg/mL；24時間 |
アプリケーション | Ganoderic Acid Aは、BV2小膠細胞のLPS誘発の増殖と活性化を著しく抑制した。Ganoderic Acid Aは、炎症促進M1表現型から抗炎症M2表現型への小膠細胞の分極を促進した。 |
| 動物実験 [2]: | |
動物モデル | 雌BALB/cマウス |
準備方法 | 1，7、14日目に、生理食塩水のなかの10mg Ovalbumin (OVA) + 1mg aluminum hydroxideを腹腔内注射したマウスを感作した。21日目から、OVAエアロゾルのチャレンジ(10mlの生理食塩水のなかの0.1g OVA、30分間)を7日間、毎日行った。Ganoderic Acid A (20または40mg/kg)を各OVAチャレンジの1時間前に、腹腔内注射した。分析のために、最後のチャレンジの後に、肺組織と血清を採取した。 |
投与形態 | 20または40mg/kg；腹腔内注射；7日間、毎日 |
アプリケーション | Ganoderic Acid AはOVA誘発の気道過敏性（AHR）を著しく軽減し、血清と肺組織で炎症細胞浸潤（好酸球、リンパ球、好中球）を減らし、血清でTh2サイトカイン(IL-4、IL-5、IL-13)とIgEのレベルを減らした。Ganoderic Acid Aは、TLR4/NF-κBシグナル経路の活性化をも抑制し、その証拠に、肺組織でTLR4、MyD88、p-NF-κBとp-IκBαの発見が減った。 |
References: | |
| Cas No. | 81907-62-2 | SDF | |
| Chemical Name | (2R,6R)-6-[(5R,7S,10S,13R,14R,15S,17R)-7,15-dihydroxy-4,4,10,13,14-pentamethyl-3,11-dioxo-2,5,6,7,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid | ||
| Canonical SMILES | CC(CC(=O)CC(C)C(=O)O)C1CC(C2(C1(CC(=O)C3=C2C(CC4C3(CCC(=O)C4(C)C)C)O)C)C)O | ||
| Formula | C30H42O7 | M.Wt | 514.65 |
| 溶解度 | DMF: 5mg/mL,DMSO: 1 mg/mL,Ethanol: 3 mg/mL | Storage | 4°C, away from moisture and light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9431 mL | 9.7153 mL | 19.4307 mL |
| 5 mM | 388.6 μL | 1.9431 mL | 3.8861 mL |
| 10 mM | 194.3 μL | 971.5 μL | 1.9431 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)